Algernon Pharmaceuticals (TSE:AGN) has released an update.
Algernon Pharmaceuticals, a Canadian drug development firm, has announced a partnership with ICP Securities Inc. to provide automated market making services for its shares using the ICP Premium™ algorithm. With an initial three-month term and potential month-to-month renewals, the engagement aims to balance the supply and demand for Algernon’s shares without additional compensation or performance-based factors. Additionally, Algernon has granted 425,000 restricted share units to an employee and a consultant, subject to regulatory approval.
For further insights into TSE:AGN stock, check out TipRanks’ Stock Analysis page.
